The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Clonal hematopoiesis & progression of asymptomatic Waldenström’s macroglobulinemia
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a study exploring the impact of clonal hematopoeisis (CH) on patients with Waldenström’s macroglobulinemia (WM). Whilst it was found that CH did not have an impact on patients with symptomatic WM, the presence of CH in patients with WM precursor states led to an increased risk of progression to symptomatic disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
